Clinical research

CenterWatch Announces: Research Practitioner Newsletter

Wednesday, April 14, 2021 - 5:00am

b'Where can one turn for timely, educational coverage of the latest developments and trends in the clinical trials field?\nTrial professionals investigators, coordinators, monitors and nurses read Research Practitioner to stay current with all the news and ideas that affect their day-to-day jobs and help them advance their careers.\nAn extra bonus for CRAs and CRCs: Research Practitioner is approved for continuing education credits by the Association of Clinical Research Professionals (ACRP).

Key Points: 
  • b'Where can one turn for timely, educational coverage of the latest developments and trends in the clinical trials field?\nTrial professionals investigators, coordinators, monitors and nurses read Research Practitioner to stay current with all the news and ideas that affect their day-to-day jobs and help them advance their careers.\nAn extra bonus for CRAs and CRCs: Research Practitioner is approved for continuing education credits by the Association of Clinical Research Professionals (ACRP).
  • CRAs and CRCs who read the articles and complete the post-tests can earn up to 18 credits a year to maintain/achieve their certification.
  • Earn up to 36 continuing education credits the first year!\nWith Research Practitioner subscribers get:\nTwo in-depth feature stories in every issue, with tests accredited by the ACRP, that can earn the reader 18 credits a year\nExpanded analysis on current trends, common trial management issues and ethical concerns to support your clinical research enterprise\n"An invaluable tool, we have provided a center-wide Research Practitioner subscription for our staff since 2006 to allow them timely access to regulatory changes and operational efficiencies, as well as clinical trial methodology training in a very digestible, informative fashion.
  • "\nEach issue goes beyond what one should do and shows one how to incorporate critical concepts and strategies to more effectively manage and execute clinical trials.\n'

eClinical Solutions Shares Business Strategies for Accelerated Clinical Trials Post Covid-19

Tuesday, April 13, 2021 - 4:30pm

b'MANSFIELD, Mass., April 13, 2021 /PRNewswire-PRWeb/ -- eClinical Solutions LLC , a global provider of cloud-based enterprise software and software-driven clinical data services that accelerate digital clinical initiatives, today announced that senior thought leaders from eClinical will speak at several key upcoming industry events.

Key Points: 
  • b'MANSFIELD, Mass., April 13, 2021 /PRNewswire-PRWeb/ -- eClinical Solutions LLC , a global provider of cloud-based enterprise software and software-driven clinical data services that accelerate digital clinical initiatives, today announced that senior thought leaders from eClinical will speak at several key upcoming industry events.
  • Their topics include increasing the speed of clinical development, navigating decentralized trial models, and supporting complex protocol designs and data proliferation.
  • "\nThe current challenges in clinical research will take center stage on Tuesday, April 13 (Americas) and Wednesday, April 14 (EMEA) in "Clinical Trials in a Post Covid-19 World."
  • Our intelligent clinical data platform and data services give our clients real-time, self-service access to all their data from one centralized location; plus advanced analytics that help them make smarter, faster business decisions.

Bioclinica Transforms Source Document Management in Clinical Trials

Tuesday, April 13, 2021 - 3:00pm

b'PRINCETON, N.J., April 13, 2021 /PRNewswire/ --Bioclinica, an integrated solutions provider of clinical life science and technology expertise, today launched Source Document Manager .

Key Points: 
  • b'PRINCETON, N.J., April 13, 2021 /PRNewswire/ --Bioclinica, an integrated solutions provider of clinical life science and technology expertise, today launched Source Document Manager .
  • This comprehensive solution enables clinical trial sponsors and contract research organizations (CROs) to collect, de-identify, translate, organize, and manage source documents seamlessly using a secure, cloud-based application.
  • "\nBioclinica Source Document Manager supports onlineprotected health information redaction at the site level with verification by a team of quality control experts and boasts direct integration with a premier online translation service to translate source documents.
  • Through deep medical, scientific, and technology expertise, the company provides medical imaging and cardiac safety services, clinical endpoint adjudication, clinical trial software, and drug safety solutions.

DFnet and ClinConsent Join Forces to Meet Growing Demand for Patient-Centric eConsent Solutions

Tuesday, April 13, 2021 - 2:00pm

b'SEATTLE, April 13, 2021 /PRNewswire-PRWeb/ --DF/Net Research, Inc. (DFnet), a trusted leader in clinical data management solutions, today announced its partnership with ClinConsent, LLC.

Key Points: 
  • b'SEATTLE, April 13, 2021 /PRNewswire-PRWeb/ --DF/Net Research, Inc. (DFnet), a trusted leader in clinical data management solutions, today announced its partnership with ClinConsent, LLC.
  • We are thrilled to partner with ClinConsent to add this trusted, patient-centric consent solution to the DFnet roster.
  • "\nClinConsent\'s eConsent solution, now known in some markets as "DFconsent" under the DFnet suite of solutions, enhances patient information exchange in clinical research.
  • "\nDFnet is hosting a webinar on May 12, 2021 to officially welcome DFconsent to the DFnet suite of clinical data management solutions.

Quartesian Signs Global Medical Technology Company to Multi-Year Clinical Data Management Services Agreement

Tuesday, April 13, 2021 - 1:30pm

b'PRINCETON, N.J., April 13, 2021 /PRNewswire/-- Quartesian , a multinational Clinical Research Organization (CRO) serving the biopharmaceutical and medical device industries, today announced a multi-year agreement with a leading portfolio medical technology company.

Key Points: 
  • b'PRINCETON, N.J., April 13, 2021 /PRNewswire/-- Quartesian , a multinational Clinical Research Organization (CRO) serving the biopharmaceutical and medical device industries, today announced a multi-year agreement with a leading portfolio medical technology company.
  • Under the agreement Quartesian is providing Electronic Data Capture (EDC) programming using Medidata Rave EDC, full data management, and SAS statistical services in support of several franchises.\nQuartesian specializes in high quality clinical data at affordable rates.
  • We specialize in EDC and have worked with Medidata clinical data technology solutions for over eight years", said Steve Boccardo, Sr. VP Business Development and Commercial Strategy for Quartesian.
  • "\nSponsors and CROs alike value Quartesian solutions to help them Take Back Control of their data and their clinical trials.\nQuartesian leverages industry-leading technologies paired with deep clinical trial expertise to help clients bring their treatments to market faster and more efficiently.\nQuartesian is the "Clinical Data Company", providing insightful data to organizations performing clinical studies.

Biohaven Highlights Neuroscience Advancements with 22 Presentations at the 2021 American Academy of Neurology (AAN) Virtual Annual Meeting

Tuesday, April 13, 2021 - 12:30pm

b'NEW HAVEN, Conn., April 13, 2021 /PRNewswire/ --Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), today announced that 22 abstracts, including three oral presentations, were accepted at the 2021 American Academy of Neurology (AAN) virtual annual meeting being held from April 17 22.

Key Points: 
  • b'NEW HAVEN, Conn., April 13, 2021 /PRNewswire/ --Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), today announced that 22 abstracts, including three oral presentations, were accepted at the 2021 American Academy of Neurology (AAN) virtual annual meeting being held from April 17 22.
  • "\nPhase 2/3 data from the pivotal randomized, placebo-controlled trial assessing rimegepant for the preventive treatment of migraine evaluated 695 patients for efficacy.
  • Patients who had a gap in troriluzole treatment (3 weeks to 12 months) showed a greater than 1 point worsening during the off-treatment period.
  • Various important factors could cause actual results or events to differ materially from those that may be expressed or implied by our forward-looking statements.

Positive Topline Data Shows Fostamatinib Meets Primary Endpoint of Safety in Phase 2 Clinical Trial in Hospitalized Patients with COVID-19

Tuesday, April 13, 2021 - 12:00pm

By day 29, there were three SAEsin the fostamatinib plusstandard of care (SOC) group of thirty patients compared to six SAEs in the placebo plus SOC group of twenty-nine patients(p=0.23).

Key Points: 
  • By day 29, there were three SAEsin the fostamatinib plusstandard of care (SOC) group of thirty patients compared to six SAEs in the placebo plus SOC group of twenty-nine patients(p=0.23).
  • We are extremely pleased with the outcome of this trial, which provides early indications of the potential positive impact of fostamatinib for patients with COVID-19," said Raul Rodriguez, president and CEO of Rigel.
  • "\n"Fostamatinib was shown to be well tolerated in hospitalized patients with COVID-19 on oxygen.
  • "\nKey findings from the Phase 2 clinical data readout include:\nAt Day 29, in the overall population there were zero deaths in the fostamatinib group of thirty patients compared to three deaths in the placebo group of twenty-nine patients (p=0.07).

Virtual Clinical Trials Market Size Worth $11.5 Billion By 2028 | CAGR: 5.7%: Grand View Research, Inc.

Tuesday, April 13, 2021 - 9:35am

b'SAN FRANCISCO, April 13, 2021 /PRNewswire/ -- The global virtual clinical trials market size is expected to reach USD 11.5 billion by 2028, according to a new report by Grand View Research, Inc.

Key Points: 
  • b'SAN FRANCISCO, April 13, 2021 /PRNewswire/ -- The global virtual clinical trials market size is expected to reach USD 11.5 billion by 2028, according to a new report by Grand View Research, Inc.
  • The market is expectedto expand at a CAGR of 5.7% from 2021 to2028.
  • The need for patient diversity clubbed with enhanced data collection in clinical trials is boosting virtual/decentralized clinical trials (DCTs) market growth.\nKey suggestions from the report:\nThe oncology segment held 25.0% of the market share in 2020.
  • Virtual clinical studies eliminate challenges posed by traditional research studies, for example, delays in patient recruitment and time-consuming procedures.

Virtual Clinical Trials Market Size Worth $11.5 Billion By 2028 | CAGR: 5.7%: Grand View Research, Inc.

Tuesday, April 13, 2021 - 9:35am

b'SAN FRANCISCO, April 13, 2021 /PRNewswire/ -- The global virtual clinical trials market size is expected to reach USD 11.5 billion by 2028, according to a new report by Grand View Research, Inc.

Key Points: 
  • b'SAN FRANCISCO, April 13, 2021 /PRNewswire/ -- The global virtual clinical trials market size is expected to reach USD 11.5 billion by 2028, according to a new report by Grand View Research, Inc.
  • The market is expectedto expand at a CAGR of 5.7% from 2021 to2028.
  • The need for patient diversity clubbed with enhanced data collection in clinical trials is boosting virtual/decentralized clinical trials (DCTs) market growth.\nKey suggestions from the report:\nThe oncology segment held 25.0% of the market share in 2020.
  • Virtual clinical studies eliminate challenges posed by traditional research studies, for example, delays in patient recruitment and time-consuming procedures.

CISCRP (Center for Information & Study on Clinical Research Participation) Boosts Awareness of Clinical Trials with AWARE Northeast Virtual Event

Monday, April 12, 2021 - 8:00pm

b'BOSTON, April 12, 2021 /PRNewswire-PRWeb/ -- CISCRP (Center for Information & Study on Clinical Research Participation), a nonprofit organization dedicated to engaging the public and patients as partners in the clinical research process, announces AWARE for All - Northeast, a virtual event focusing on engaging diverse communities to ensure representation and inclusive clinical research for the future.

Key Points: 
  • b'BOSTON, April 12, 2021 /PRNewswire-PRWeb/ -- CISCRP (Center for Information & Study on Clinical Research Participation), a nonprofit organization dedicated to engaging the public and patients as partners in the clinical research process, announces AWARE for All - Northeast, a virtual event focusing on engaging diverse communities to ensure representation and inclusive clinical research for the future.
  • While awareness of clinical research has never been higher, there is still a lack of clarity and understanding about clinical trial participation among the general public.\n"The main concern has been mis-trust and mis-education.
  • Bringing education and addressing concerns directly, helps," says AWARE for All - Northeast panelist, Christian Ramirez Martinez, Clinical Research Enrollment Manager at Columbia University Irving Medical Center\'s All of Us Research Program.
  • Community events like AWARE help bring information about clinical research and the benefits of participating in it.